[下肢慢性缺血患者的抗血栓治疗:仅用阿司匹林治疗是否足够?]
K A Andreychuk1,2, G Yu Sokurenko1
1All-Russian Center of Emergency and Radiation Medicine named after A.M. Nikiforov of the Ministry of Emergency Situations of Russia, 197082, Saint Petersburg, Russian Federation.
Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery
|February 28, 2026
概括
周围动脉疾病 (PAD) 患者从新的抗血栓策略中受益. 结合抗血小板药物和低剂量里瓦洛克萨班改善了结果,并降低了PAD的血栓形成风险,包括关键四肢缺血.
科学领域:
- 血管医学 血管医学
- 心血管药理学心血管药理学
背景情况:
- 周围动脉疾病 (PAD) 具有显著的发病率和不理想的治疗结果,特别是在关键四肢缺血中.
- 重血管后的血栓性并发症会对患者的死亡率和残疾产生负面影响.
- 目前的抗血小板治疗是PAD中对血栓形成的主要基于证据的策略.
研究的目的:
- 评估PAD患者新型抗血栓治疗方案的安全性和有效性.
- 探索口服抗凝剂在PAD管理中的作用.
- 评估PAD中抗血小板药物与里瓦罗克萨班的组合.
主要方法:
- 对临床试验的审查,包括VOYAGER PAD试验.
- 对结合抗血小板药物和口服抗凝剂的治疗方案的分析.
- 对PAD患者里瓦洛克萨班 (2.5毫克每天两次) 的安全性和疗效数据的评估.
主要成果:
- 口服抗凝剂,如利瓦洛克萨班,显示在PAD的抗血栓预防中具有潜力.
- 旅行者PAD试验证明了将抗凝血剂整合到PAD治疗中的可行性.
- 与抗血小板药物和里瓦洛克萨班 (每天两次2.5毫克) 的联合治疗被证明是安全和有效的.
结论:
- 里瓦罗克萨班与抗血小板治疗结合使用,为PAD的抗血小板预防提供了一个可行的选择.
- 这种疗法对保守管理和再血管化后的PAD患者都有效.
- 新型抗凝剂策略在治疗PAD并发症方面取得了重大进展.
相关概念视频
Venous Thrombosis III: Interprofessional Care
423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
Peripheral Artery Disease III: Interprofessional Care
443
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
443
Venous Thrombosis IV: Nursing Management
324
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
324
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Peripheral Artery Disease V: Postoperative Nursing Management
480
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
480
Atherosclerosis III: Management
520
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
520


